Research analysts who have asked questions during Galmed Pharmaceuticals earnings calls.
Kristen Kluska
Cantor Fitzgerald
3 questions for GLMD
Also covers: ABEO, ADMA, AQST +24 more
Edward Nash
Canaccord Genuity
2 questions for GLMD
Also covers: CORT, VERU
Timur Ivannikov
Raymond James
2 questions for GLMD
Also covers: APLS, BLTE, IFRX +2 more
Justin Zelin
BTIG, LLC
1 question for GLMD
Also covers: BCAB, CASI, IMCR +9 more
NR
Naz Rahman
Maxim Group
1 question for GLMD
Also covers: ASRT, AYTU, NXGL +3 more
Ryan Deschner
Raymond James Financial
1 question for GLMD
Also covers: APLS, ARDX, ARSP +7 more
SS
Steven Seedhouse
Raymond James
1 question for GLMD
Also covers: APLS, BCRX, EDIT +2 more
TY
Thomas Yip
H.C. Wainwright & Co.
1 question for GLMD
Also covers: ABUS, ARDX, ENTA +6 more
Recent press releases and 8-K filings for GLMD.
Galmed Pharmaceuticals Ltd. to hold Special General Meeting to vote on reverse stock split
GLMD
Delisting/Listing Issues
Proxy Vote Outcomes
- Galmed Pharmaceuticals Ltd. (GLMD) will hold a Special General Meeting of Shareholders on March 4, 2026, to vote on a proposal to approve a framework for a reverse split of its Ordinary Shares.
- The proposed reverse split framework allows for a ratio between 1:2 and 1:250, to be implemented at the discretion of the board of directors within 18 months following the meeting.
- The primary intent of this action is to increase the share price to regain compliance with the Nasdaq minimum bid price requirement of $1.00 per share.
- The Company received a notice from Nasdaq on January 29, 2026, indicating non-compliance with this requirement.
- As of February 6, 2026, the closing price of GLMD's Ordinary Shares on the Nasdaq Capital Market was $0.6639.
Feb 9, 2026, 9:15 PM
Galmed Pharmaceuticals Announces Nasdaq Minimum Bid Price Notification
GLMD
Delisting/Listing Issues
- Galmed Pharmaceuticals Ltd. received a letter from Nasdaq Listing Qualifications indicating non-compliance with the minimum bid price requirement of $1.00 per share.
- The company has a compliance period of 180 calendar days, from January 29, 2026, until July 28, 2026, to regain compliance.
- To regain compliance, the closing bid price of its ordinary shares must be at least $1 for a minimum of ten consecutive business days.
- This notification has no immediate effect on the company's Nasdaq listing or the trading of its ordinary shares, which will continue under the symbol "GLMD".
Jan 30, 2026, 9:20 PM
Galmed Announces New Use Patent for Aramchol Combination Therapy
GLMD
New Projects/Investments
- Galmed Pharmaceuticals Ltd. announced the grant of a new Use Patent in South Korea for the combination therapy of Aramchol and Rezdiffra (Resmetirom) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis.
- This new patent extends Aramchol's patent protection worldwide to July 2042 in the U.S. and is added to earlier patents granted in the United States, Europe, and Canada.
- Aramchol is a first-in-class, Phase 3 ready drug candidate that has shown robust fibrosis improvement and is considered ideal for combination with other MASH drugs due to its excellent safety and tolerability.
Dec 4, 2025, 1:42 PM
Galmed Pharmaceuticals Announces New Patent for Aramchol Combination Therapy
GLMD
New Projects/Investments
- Galmed Pharmaceuticals has been granted a new Use Patent in South Korea for its lead compound, Aramchol.
- The patent covers the combination therapy of Aramchol and Rezdiffra (resmetirom) for treating non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis.
- This new patent extends Aramchol's patent protection worldwide to July 2042.
- CEO Allen Baharaff highlighted the industry's shift towards combination therapies for MASH, noting Aramchol's suitability due to its safety and tolerability.
Dec 4, 2025, 1:30 PM
Galmed Pharmaceuticals Ltd. Issues CEO Letter to Shareholders Highlighting Financial Strength and Expanded Clinical Pipeline
GLMD
New Projects/Investments
Guidance Update
- Galmed Pharmaceuticals Ltd. reported a strong financial position as of Q3 2025, with approximately $19.2 million in cash and practically zero debt, maintaining a minimal burn rate of approximately $1.5 million per quarter.
- The company is expanding the clinical development path for Aramchol beyond liver disease to include oncology and cardiometabolic indications, aiming for short and long-term value creation.
- Aramchol demonstrated robust fibrosis improvement in the Phase 3 ARMOR study for MASH and liver fibrosis, with 65% and 100% of patients experiencing fibrosis improvement at week 48 by paired and AI evaluations, respectively.
- Galmed plans to initiate a Phase 1/2 clinical trial in early 2026 for metastatic colorectal cancer, hepatocellular carcinoma, and cholangiocarcinoma, based on pre-clinical data showing Aramchol enhances activity and overcomes drug resistance in GI tumor models.
Dec 1, 2025, 1:38 PM
Galmed Pharmaceuticals Issues CEO Letter to Shareholders Highlighting Financial Strength and Clinical Advancements
GLMD
New Projects/Investments
Guidance Update
- Galmed Pharmaceuticals reported a strong financial position, ending Q3 2025 with approximately $19.2 million in cash and practically zero debt, while maintaining a minimal burn rate of approximately $1.5 million per quarter.
- The company is expanding its therapeutic focus for Aramchol beyond liver disease, with plans to advance into Phase 1/2 clinical trials in early 2026 for gastrointestinal oncology indications, including metastatic colorectal cancer, hepatocellular carcinoma, and cholangiocarcinoma.
- Aramchol demonstrated robust fibrosis improvement in MASH and liver fibrosis, with 65% to 100% of patients showing improvement at week 48 in the ARMOR study, and the company is developing a new sublingual formulation for a Phase 2 MASH clinical study.
- Galmed is also developing a novel subcutaneous formulation of Aramchol to explore its potential in cardiometabolic diseases, systemic inflammation, and broader metabolic-cardiovascular indications.
Dec 1, 2025, 1:30 PM
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Updates
GLMD
Earnings
New Projects/Investments
- Galmed Pharmaceuticals Ltd. reported a net loss of approximately $2.0 million, or $0.33 per share, for the three months ended September 30, 2025, compared to a net loss of approximately $1.9 million, or $2.31 per share, for the same period in 2024.
- As of September 30, 2025, the company's cash and cash equivalents, short term deposits, restricted cash, and marketable debt securities totaled approximately $19.2 million. During 2025, Galmed raised approximately $9.3 million through its equity line and ATM facilities.
- The company announced positive top-line results from its joint research with Virginia Commonwealth University evaluating Aramchol's effect on overcoming drug resistance in gastrointestinal cancers and from its AM-001 Study, a Phase 1 bioavailability study of Aramchol Meglumine.
- Management believes existing funds will be sufficient to continue business and operations for more than 12 months from the report's issuance date of November 26, 2025.
Nov 26, 2025, 1:57 PM
Galmed Pharmaceuticals Reports Q3 2025 Financial Results and Business Updates
GLMD
Earnings
New Projects/Investments
- Galmed Pharmaceuticals reported a net loss of approximately $2.0 million, or $0.33 per share, for the three months ended September 30, 2025.
- As of September 30, 2025, the company's cash and cash equivalents, short-term deposits, restricted cash, and marketable debt securities totaled approximately $19.2 million, an increase from $15.4 million at December 31, 2024.
- Research and development expenses increased to approximately $1.1 million for the three months ended September 30, 2025, while general and administrative expenses decreased to approximately $1.0 million for the same period.
- In November 2025, Galmed announced positive top-line results from joint research on Aramchol's effect on overcoming drug resistance in GI cancers and meaningful top-line results from its AM-001 Phase 1 bioavailability study of Aramchol Meglumine. Additionally, the company raised approximately $9.3 million through its equity line and ATM facilities during 2025.
Nov 26, 2025, 1:30 PM
Galmed Announces Positive Top-Line Results from AM-001 Study
GLMD
New Projects/Investments
Guidance Update
- Galmed Pharmaceuticals Ltd. announced meaningful top-line results from its AM-001 Study of Aramchol meglumine on November 18, 2025.
- The study demonstrated that Aramchol meglumine granules have significantly greater bioavailability (5-fold for 400mg and 3-fold for 200mg) compared to Aramchol free acid tablets.
- This improved pharmacokinetic profile allows for a once-daily therapeutic regimen, which is expected to enhance adherence and reduce the drug's cost of goods by approximately 50%.
- The optimal dose for subsequent clinical trials has been identified as 400mg oral once daily administration.
- These results will inform the upcoming oncology Phase 2 studies planned for the first half of 2026.
Nov 18, 2025, 1:48 PM
Galmed Announces Positive Top-Line Results from AM-001 Study of Aramchol Meglumine
GLMD
New Projects/Investments
- Galmed Pharmaceuticals announced positive top-line results from its AM-001 Phase 1 Bioavailability (BA) Study of Aramchol meglumine.
- The study showed that Aramchol meglumine granules have significantly greater bioavailability (5-fold for 400mg and 3-fold for 200mg) compared to Aramchol free acid tablets.
- This improved pharmacokinetic profile allows for a once-daily therapeutic regimen, which is expected to enhance patient adherence and potentially reduce the drug's cost of goods by approximately 50%.
- The optimal dose for future oncology Phase 2 studies, planned for H1 2026, has been identified as 400mg oral once daily administration.
Nov 18, 2025, 1:30 PM
Quarterly earnings call transcripts for Galmed Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more